Foveal Thickness Fluctuations: A Hidden Hurdle in CRVO-ME Management?

Fellow ophthalmologists, take note! This new study delves into the complexities of treating central retinal vein occlusion with macular edema (CRVO-ME) and highlights the potential impact of foveal thickness fluctuations (FTF) on long-term outcomes.

The Study:

This retrospective, multicenter study followed 141 treatment-naive patients with CRVO-ME receiving anti-VEGF injections based on a pro re nata (PRN) regimen. By analyzing foveal thickness (FT) using OCT at each visit, researchers categorized patients into four groups based on increasing FTF.

Key Findings:

  • Visual acuity (BCVA) and FT improved overall, suggesting the effectiveness of anti-VEGF treatment.
  • However, higher FTF was associated with worse final BCVA and a longer foveal ellipsoid zone (EZ) band defect, indicating impaired photoreceptor function.
  • Interestingly, neovascular complications did not show a direct link to FTF, suggesting other factors might be at play.

Implications for Practice:

  • Monitoring FTF alongside traditional parameters like BCVA and OCT findings could provide valuable insights into treatment response and prognosis.
  • Patients with higher FTF might benefit from more frequent monitoring or adjustments to their treatment regimen, potentially including earlier intervention or combination therapies.
  • Further research is needed to understand the mechanisms underlying FTF and explore strategies to minimize its impact on visual outcomes.

Take-Home Message:

While anti-VEGF injections remain the mainstay of CRVO-ME treatment, FTF emerges as a potential factor influencing long-term visual function. Incorporating FTF assessment into our clinical practice might refine treatment approaches and ultimately improve patient outcomes.

با دوستان خود به اشتراک بگذارید: 

پستهای اخیر:

مابین نوشته ها ٬ ژورنال کلابها و پادکستهای فارابی رتینا جستجو کنید: 

  • 0
  • 22
  • 13
  • 439
  • 1403-04-19